- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03164889
Clinical and Basic Research of ETV Plus GM-CSF in Chronic Hepatitis B Patients
March 9, 2022 updated by: Beijing 302 Hospital
Clinical and Basic Research of Relationship Between Hepatitis B Virus Quasi-Species Evolution and Function of Natural Killer Cells With Antiviral Therapy Response in Chronic Hepatitis B Patients
Previous studies indicated that Granulocyte Macrophage-colony Stimulating Factor (GM-CSF) could improve survival rate in patients with acute liver failure and obtain higher HBsAg seroconversion rate when in combination with peg-interferon for chronic hepatitis B (CHB) patients.
In this study, investigators will study the clinical effect of entecavir (ETV) plus GM-CSF in patients with CHB compared to ETV monotherapy.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Antiviral treatment plays critical role in treatment of chronic HBV infection.
Entecavir, an nucleos(t)ide analogs (NA) targeting the viral polymerase, is widely used in China as the first line drug in antiviral treatment for CHB patients.
The sustained suppression of serum HBV DNA to undetectable level has been proven to be associated with the prevention of progression of liver disease and inhibition of the development of hepatocellular carcinoma.
According to data published, a rate about 70% HBVDNA undetectable could be reached after 1 year therapy.
However, the rate of HBsAg loss is very low about 0% to 1%.
Granulocyte-macrophage colony-stimulating factor(GM-CSF) is an important cytokine for the generation and propagation of antigen-presenting cells and for priming a cellular immune response.
It increases the production of macrophage precursors and, in turn,enhances the T-helper cell (Th cell)-mediated cytotoxicity and regulates the tumoricidal cytokines.
Previous studies indicated that when combined with IFN in patients with chronic HBV infection, it increased the therapeutic efficacy of the latter.
Recent studies showed that GM-CSF benefit patients with acute liver failure.
In this study, entecavir (ETV) plus GM-CSF would be used in patients with CHB compared to ETV monotherapy.
Primary objective of the study is to see if there is significant improvement in HBsAg loss, rates of HBeAg loss and HBV undetectable are also to be observed.
Function of NK cell from the patients enrolled will be measured during the therapy.
Study Type
Interventional
Enrollment (Actual)
80
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100039
- 302 Military Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- HBsAg positive for more than 6 months
- HBeAg positive
- ALT≥80U/L or inflammation score ≥2 of histological examination
Exclusion Criteria:
- History of drug allergy to GM-CSF
- coinfection with HCV, HIV, HAV, HEV
- liver cirrhosis or CHILD score >7
- diagnosis of hepatocellular carcinoma or AFP>100ng/ml
- Allergic thrombocytopenic purpura
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ETV+GM-CSF
Entecavir (ETV) plus Granulocyte Macrophage-colony Stimulating Factor (GM-CSF).
ETV was given 0.5mg/d, oral; GM-CSF was given 100ug, the 3th, 4th, 5th day at week1, 4, 12, 24, 48, subcutaneous injection.
|
The intervention drug was used as an immunomodulator in order to improve rates of HBsAg loss and HBeAg loss.
Other Names:
Antiviral drug for hepatitis b virus (HBV)
Other Names:
|
Active Comparator: ETV monotherapy
As standard antiviral therapy, Entecavir was given 0.5mg/d, oral.
|
Antiviral drug for hepatitis b virus (HBV)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate of HBsAg loss
Time Frame: 48 weeks after therapy
|
48 weeks after therapy
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate of HBeAg loss
Time Frame: 48 weeks after therapy
|
48 weeks after therapy
|
HBVDNA undetectable rate
Time Frame: 48 weeks after therapy
|
48 weeks after therapy
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Ping Zhao, Director, 302 Military Hospital, Beijing, China
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2017
Primary Completion (Actual)
January 1, 2018
Study Completion (Actual)
December 1, 2021
Study Registration Dates
First Submitted
November 15, 2016
First Submitted That Met QC Criteria
May 23, 2017
First Posted (Actual)
May 24, 2017
Study Record Updates
Last Update Posted (Actual)
March 24, 2022
Last Update Submitted That Met QC Criteria
March 9, 2022
Last Verified
January 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis B
- Hepatitis
- Hepatitis A
- Hepatitis B, Chronic
- Hepatitis, Chronic
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antiviral Agents
- Antineoplastic Agents
- Immunologic Factors
- Entecavir
- Sargramostim
- Molgramostim
Other Study ID Numbers
- 首发2014-2-5033
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis B, Chronic
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Gilead SciencesNot yet recruiting
-
Tongji HospitalGilead SciencesRecruiting
-
Jiangsu HengRui Medicine Co., Ltd.Unknown
-
Changhai HospitalCompleted
-
Tongji HospitalChia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownChronic Hepatitis b
-
Zhongshan Hospital Xiamen UniversityUnknownHealthy | Chronic Hepatitis B InfectionChina
-
Brii Biosciences LimitedVir Biotechnology, Inc.Active, not recruitingChronic Hepatitis B Virus InfectionSingapore, Thailand, Australia, China, Korea, Republic of
-
Nanfang Hospital of Southern Medical UniversityRecruiting
-
IlDong Pharmaceutical Co LtdRecruitingChronic Hepatitis bKorea, Republic of
Clinical Trials on Granulocyte Macrophage-colony Stimulating Factor
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingBreast Ductal Carcinoma In SituUnited States
-
Shanghai Pulmonary Hospital, Shanghai, ChinaUnknownPulmonary Alveolar ProteinosisChina
-
Lei LiRecruitingFebrile Neutropenia | Epithelial Ovarian Cancer | Adverse Event | Cost-effectiveness | Myelosuppression Adult | Colony Stimulating FactorsChina
-
University of Colorado, DenverNational Cancer Institute (NCI); Children's Hospital ColoradoCompletedEpendymoma | Ependymoma, Recurrent ChildhoodUnited States
-
Xiamen Amoytop Biotech Co., Ltd.Shanghai Jiao Tong University Affiliated First People's HospitalCompleted
-
GlaxoSmithKlineCompletedEpilepsyBulgaria, Belgium, Thailand, Denmark, Russian Federation, Italy, Spain, Ukraine, Netherlands, Germany, France, Poland
-
Northern California Melanoma CenterBayer; Melanoma Research InstituteCompleted
-
Institute of Liver and Biliary Sciences, IndiaCompletedSpontaneous Bacterial PeritonitisIndia
-
University of LiegeCompleted
-
Lei LiBeijing Hospital; China-Japan Friendship Hospital; Navy General Hospital, Beijing and other collaboratorsUnknownQuality of Life | Epithelial Ovarian Cancer | Chemotherapy-induced Neutropenia | Overall Survival | Progression-free Survival | Febrile Neutropenia, Drug-Induced | Colony Stimulating Factors Adverse Reaction | Granulocyte Colony Stimulating Factor | Cost-effectiveness AnalysisChina